Eurofins Technologies Launches an Enhanced Variant of Concern-Discriminating PCR Test Including the South African Variant (B.1.351)

Eurofins Technologies Launches an Enhanced Variant of Concern-Discriminating PCR Test Including the South African Variant (B.1.351)




Eurofins Technologies Launches an Enhanced Variant of Concern-Discriminating PCR Test Including the South African Variant (B.1.351)

LUXEMBOURG–(BUSINESS WIRE)–Eurofins Technologies announces the launch of its GSD NovaType II, its upgraded RT-PCR kit for the identification of mutations associated with SARS-CoV-2 variants of concern.

The first GSD NovaType RT-PCR kit was launched in February 2021 and quickly supported health authorities in the detection of variants in more than 100,000 COVID-19 positive patients across Europe. The new GSD NovaType II kit can now detect the N501Y and E484K mutations common to most VOC (Variants Of Concern) and the K417N mutation (specific to B.1.351 first identified in South Africa), with a high sensitivity.

The GSD NovaType II kit delivers results under two hours. It is therefore well suited to timely screening and relieving sequencing capacities for use in epidemiological studies.

Fast-paced screening for these emerging variants that may spread more easily, cause more severe disease, or may escape the body’s immune response even post vaccination, is a critical element to containing the pandemic. Laboratories can use the GSD NovaType II SARS-CoV-2 kit to identify genomic mutations in extracted samples that have already been tested positive for the presence of SARS-CoV-2 RNA.

The GSD NovaType II SARS-CoV-2 kit contains specific primers and probes for amplification and simultaneous detection of specific RNA sequences which represent specific SARS-CoV-2 S gene variants. It is delivered in a ready-to-use format with optional interpretation software. The assay has been validated on the AriaMxTM and AriaDxTM qPCR platforms from Agilent Technologies and will soon be validated on additional thermocyclers. The assay is currently for Research Use Only, but the CE-IVD mark is expected shortly.

Eurofins Technologies is at the forefront of COVID-19 detection and is continuously monitoring the emergence of new SARS-CoV-2 variants of concern and developing new products to meet the rapidly evolving challenges.

For more information, please visit Eurofins Technologies website.

Notes to Editors:

For more information, please visit www.eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Rodrigo Berlie

CustomerService@novatec-id.com
ir@eurofins.com